Acquiring Company
Momentum Biotechnologies
Acquired Company
OmicScouts
Billerica
FreisingBiotechnologyPharmaceuticalBiopharmaBiotechnologyDescription
Momentum Biotechnologies has announced the successful acquisition of OmicScouts GmbH, enhancing its mass spectrometry-based services. This acquisition allows Momentum to expand its offerings and geographic reach into the European market. Both companies align in their technical foundations and client relationships, making the acquisition a strategic fit. OmicScouts will operate as a subsidiary of Momentum.
Quick answer
Momentum Biotechnologies is acquiring OmicScouts, announced March 5, 2025. Momentum Biotechnologies is based in Billerica, Massachusetts, United States.
- How much did Momentum Biotechnologies pay for OmicScouts?
- The deal value was not disclosed.
- What does Momentum Biotechnologies do?
- Momentum Biotechnologies is a drug discovery partner providing specialized, cutting-edge mass spectrometry technologies to biopharmaceutical clients across the globe.
- Where are Momentum Biotechnologies and OmicScouts based?
- Momentum Biotechnologies is based in Billerica, Massachusetts, United States. OmicScouts is based in Freising, Bayern, Germany.
- Who are the decision-makers at Momentum Biotechnologies?
- Fundz holds 1 contact at Momentum Biotechnologies. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Pharmaceutical and Biopharma
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- AbbVie to acquire Cerevel for $45 per share (April 15, 2025)
- AbbVie acquires Cerevel Therapeutics for $45 per share (March 31, 2025)
- OS Therapies completes acquisition of Advaxis assets from Ayala Pharmaceuticals (April 12, 2025)
- Lupin acquires UK-based Renascience Pharma (April 3, 2025)
- Alvotech acquires Xbrane's R&D operations in Sweden (March 20, 2025)
- GSK completes acquisition of IDRx, Inc. to enhance precision therapeutics for treating gastrointestinal stromal tumours (February 24, 2025)
Who to call at Momentum Biotechnologies, and when
When Momentum Biotechnologies changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Momentum Biotechnologies raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Momentum Biotechnologies, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Momentum Biotechnologies. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Momentum Biotechnologies makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired OmicScouts?
OmicScouts was acquired by Momentum Biotechnologies, based in Billerica. The deal was reported on March 5, 2025. Momentum Biotechnologies is a drug discovery partner providing specialized, cutting-edge mass spectrometry technologies to biopharmaceutical clients across the globe. Momentum Biotechnologies is privately held and operates in Biotechnology.
When did Momentum Biotechnologies acquire OmicScouts?
Momentum Biotechnologies's acquisition of OmicScouts was reported on March 5, 2025. Momentum Biotechnologies has announced the successful acquisition of OmicScouts GmbH, enhancing its mass spectrometry-based services. This acquisition allows Momentum to expand its offerings and geographic reach into the European market. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does OmicScouts do?
OmicScouts integrates quantitative mass spectrometry-based proteomics and bioinformatics with biochemical and cell culture services to advance client's drug discovery, disease biology, and clinical research. It is privately held, operating in Biotechnology, and is based in Freising.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.